| Object;ive:A retrospective study was conducted to evaluate the efficacy and safety of Yangxue Qingnao Keli(YQK)on the treatment of post-stroke depression,and to provide a basis for clinical treatment.Methods:A multicenter,before-after study was conducted.A total of 137 eligible patients were allocated into the experimental group,the combined treatment group and the control group.All the patients received basic treatment,including secondary prevention drugs such as antiplatelet and anticoagulant for ischemic stroke and routine treatment for basic diseases such as hypertension,diabetes and hyperlipidemia.Otherwise,the experimental group(YQK group)was given YQK treatment(4g,3/d);The combined treatment group(YQK+sertraline group)was given YQK(4g,3/d)and sertraline hydrochloride tablets(50mg,1/d);The control group(sertraline group)was given sertraline hydrochloride tablets(50mg,1/d).The course of treatment was 12 weeks.Treatment responses were defined as changes in the MADRS、HAMD17 and HAMA between baseline and 12 weeks.The NIHSS was also evaluated at 0 and 12th week to record neurological functional recovery.The adverse reactions during treatment were recorded.SPSS Statistics 26.0 was used for data statistical analysis to evaluate the clinical efficacy of YQK in the treatment of post-stroke depression.RESULTS:A total of 137 cases were included in this study,of which 1 case was lost to follow-up.In YQK group,64 patients were included but only 63 patients finished the study,including 41 males and 22 females,with an average age of 65.87±8.73 years old.In the combined treatment group,there were 42 patients,including 22 males and 20 females,with an average age of 64.43±9.56 years old.There were 31 patients in sertraline group,including 25 males and 6 females,with an average age of 62.26±8.46.1 MADRS:Significant improvement of MADRS was found in the three groups,and the improvement was as follows(minus score):8.00(5.00,10.00)in YQK group;6.00(3.00,8.50)in the combined treatment group;7.00(4.00,12.00)in the sertraline group.The efficacy of the three groups was similar(P=0.201>0.05):the combined treatment group≈YQK group≈Sertraline group.2 HAMD17:Significant improvement of HAMD17 was found in the three groups,and the improvement was as follows(minus score):7.00(4.00,8.00)in YQK group;6.19±4.391in the combined treatment group;5.35±3.980 in the sertraline group.The efficacy of the three groups was similar(P=0.327>0.05):the combined treatment group≈YQK group≈Sertraline group.3 HAMA:Significant improvement of HAMA was found in the three groups,and the improvement was as follows(minus score):3.00(1.00,5.00)in YQK group;2.00(1.00,7.00)in the combined treatment group;1.00(1.00,3.00)in the sertraline group.The efficacy of the three groups was significant different(P=0.017<0.05):the combined treatment group≈YQK group>the sertralin group.4 NIHSS:Significant improvement of NIHSS was found in the three groups,and the improvement was as follows(minus score):1.00(0.00,2.00)in YQK group;1.00(0.00,3.25)in the combined treatment group;1.00(0.00,3.00)in the sertraline group.The efficacy of the three groups was similar(P=0.616>0.05):the combined treatment group≈YQK group≈the sertraline group.5 Adverse events:Two patients in the sertraline group showed elevated liver enzymes after treatment,and the rest had no obvious adverse reactions or events.CONCLUSIONS:YQK conbined with sertraline can effectively relieve the symptoms of anxiety and depression after stroke,and improve post-stroke neurological functional deficit,without any adverse events.This study provides clinical evidence for the treatment of PSD. |
